• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Lupin launches generic Vigamox Ophthalmic solution in the US

financialexpressJuly 06, 2017

Tag: Generic , lupin

The product is being manufactured at the company’s Pithampur facility

Lupin has announced the launch of its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5 per cent (base) having received an approval from the United States Food and Drug Administration (FDA) earlier. The launched product is from Lupin’s Pithampur manufacturing facility.

Lupin’s Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5 per cent (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.’s Vigamox Ophthalmic solution. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms.

Previous:Merck awards €1.25 million to research projects through its 2017 Grant for Fertility Innovation (GFI

Next:Zydus starts phase II trial of ZYAN1 for treating anaemia in patients with CKD

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Lupin launches generic Vigamox Ophthalmic solution in the US | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Generic Soft Mist Inhaler

Generic Soft Mist Inhaler
Generic Breezhaler

Generic Breezhaler
Lupeol-8%-Lupinus Albus Extracts

Lupeol-8%-Lupinus Albus Extracts
20mm crimp on nasal pump, Dosed, Generic to, AB rated

20mm crimp on nasal pump, Dosed, Generic to, AB rated
Generic Diskus

Generic Diskus
Lupeol-98%-Lupinus Albus Extracts

Lupeol-98%-Lupinus Albus Extracts
Nasal pump for Generics

Nasal pump for Generics
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service